AMRX Amneal Pharmaceuticals, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$18.1

Period return

+4.52 (+33.28%)

Volume

2.0M

2026-07-21O $17.59 H $18.18 L $17.44 C $18.1MA5 $17.74MA20 $17.24MA60 $14.76MA120 $14.04

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 04.Highin 14 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 20.LowBUY2 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 04. 17.MediumBUY3 months ago
UBS: Buy
US analyst rating / recommendation change.
2026. 03. 02.LowBUY5 months ago
Truist Securities: Buy
US analyst rating / recommendation change.
2025. 12. 10.MediumBUY7 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2025. 11. 01.LowBUY9 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2025. 09. 16.LowBUY10 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $17.2 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 04.	After market close (AMC)	$0.23	—	—	$759.23M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.04	—	—	$695.42M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.28	—	—	$2.06B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.28	—	—	$1.36B	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	301,028	$3.79M	0.01%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	282,677	$3.51M	0.00%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	78,105	$970.85K	0.00%	—	New position

Amneal Pharmaceuticals, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 20.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 04. 17.	UBS	—	Initiate coverage	— → Buy	—	UBS: Buy
2026. 03. 02.	Truist Securities	—	Maintain	Buy → Buy	—	Truist Securities: Buy
2025. 12. 10.	Barclays	—	Initiate coverage	— → Overweight	—	Barclays: Overweight
2025. 11. 01.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2025. 09. 16.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight